Augmentin 500 mg/125 mg is a conventional immediate-release prescription antibiotic tablet containing 500 mg of amoxicillin and 125 mg of clavulanic acid, supplied as clavulanate potassium. Amoxicillin is a penicillin-class antibacterial, while clavulanate inhibits certain beta-lactamase enzymes that can inactivate susceptible penicillin antibiotics. The complete 500/125 mg designation identifies a two-component combination product, not a plain amoxicillin 500 mg tablet. This distinction matters when reviewing prescription records, pharmacy catalogs and generic medication labels in the United States.
The conventional 500/125 mg tablet has a 4:1 amoxicillin-to-clavulanic-acid ratio. Both quantities are essential to product identification because standard Augmentin tablets come in several strength pairs, and differences in clavulanate content can prevent direct substitution. For example, two conventional 250/125 mg tablets contain 500 mg of amoxicillin but 250 mg of clavulanic acid, making them different from one 500/125 mg tablet. FDA labeling also distinguishes this immediate-release tablet from Augmentin XR, chewable tablets and oral suspensions. Some formulation changes are recognized under specific FDA conditions, but the shared ingredient names do not establish unrestricted interchangeability.
For someone with an existing U.S. prescription, the practical task is to verify that the pharmacy is dispensing the intended 500/125 mg combination tablet, whether branded or an appropriately approved generic. This involves checking the complete strength pair, dosage form, actual product labeling, manufacturer or labeler and relevant package identifiers. FDA approval and published labeling do not guarantee that a particular branded or generic package is currently stocked. This page concentrates on the 500/125 mg immediate-release tablet and its product-specific identification requirements; the broader Augmentin tablet guide compares the complete conventional tablet family.
The conventional Augmentin 500 mg/125 mg tablet is a fixed-combination oral antibacterial medicine containing amoxicillin and clavulanate potassium. Each tablet provides 500 mg of amoxicillin, supplied as amoxicillin trihydrate, and 125 mg of clavulanic acid, supplied as its potassium salt. These amounts describe one tablet rather than a complete treatment course or an individualized dosing recommendation.
The product belongs to the standard immediate-release Augmentin tablet family. This formulation differs from Augmentin XR extended-release tablets and from chewable or liquid products with other component concentrations. The specific 500/125 mg strength pair is part of the tablet's identity and should remain visible in prescription records and pharmacy labels.
Amoxicillin interferes with bacterial cell-wall synthesis, while clavulanate inhibits certain beta-lactamase enzymes that can make susceptible bacteria resistant to amoxicillin alone. The combination can therefore retain activity against some organisms for which plain amoxicillin may be inadequate. However, it does not overcome every resistance mechanism and is not automatically the preferred antibiotic for every bacterial infection.
The Augmentin name identifies the proprietary brand, whereas generic tablets are commonly marketed using established names such as amoxicillin and clavulanate potassium. An FDA-approved generic corresponding to the same reference product may differ in appearance, inactive ingredients, manufacturer and packaging while meeting applicable regulatory requirements. Whether a specific generic may be substituted depends on the approved product, prescription and relevant dispensing rules.
The Augmentin brand guide explains the wider brand family, while the generic amoxicillin/clavulanate guide addresses the broader category of two-ingredient combination products. This page focuses on the individual 500/125 mg conventional tablet.
The two numbers in the 500 mg/125 mg designation represent separate quantities of active components. The first identifies 500 mg of amoxicillin, and the second identifies 125 mg of clavulanic acid. Both are required to distinguish the combination from single-ingredient amoxicillin products and from other amoxicillin/clavulanate formulations.
The 4:1 amoxicillin-to-clavulanic-acid ratio is a description of the tablet's composition. It does not indicate that the medicine is four times more effective than another antibiotic, nor does it establish a preferred strength or regimen. Ratios are useful for comparing product identities because different Augmentin formulations can contain different proportions of the same two ingredients.
Clavulanate potassium is the pharmaceutical salt used to supply clavulanic acid. FDA strength labeling expresses the 125 mg quantity as clavulanic acid rather than the total mass of the potassium salt. This convention is important when interpreting official labels and comparing branded and generic products.
The conventional 500/125 mg tablet contains the same nominal amount of clavulanic acid as the conventional 250/125 mg and 875/125 mg tablets, but a different amount of amoxicillin. Consequently, the three tablet strengths have different component ratios. Their distinct identities should not be reduced to a single amoxicillin strength or an estimated total milligram quantity.
When a prescription or pharmacy quote abbreviates the product as Augmentin 500 mg, the full 500/125 mg strength pair should be confirmed. The second number is not optional, because it identifies an active component that materially affects the composition of the medicine.
| Product characteristic | FDA-labeled information | Identification significance |
|---|---|---|
| Amoxicillin | 500 mg per tablet, supplied as amoxicillin trihydrate | Identifies the antibacterial component. |
| Clavulanic acid | 125 mg per tablet, supplied as clavulanate potassium | Identifies the beta-lactamase inhibitor component. |
| Ingredient ratio | 500:125, equivalent to 4:1 | Distinguishes this product from other combination strength pairs. |
| Dosage form | Conventional immediate-release oral tablet | Separates the product from XR, chewable and suspension formulations. |
| Product category | Prescription amoxicillin/clavulanate combination | Distinguishes the medicine from plain amoxicillin 500 mg. |
| Regulatory identity | Brand product or appropriately approved corresponding generic | Requires verification of the actual application, label and dispensed product. |
The July 2026 FDA prescribing information describes the original branded Augmentin 500 mg/125 mg tablet as a white, oval, film-coated tablet. It is debossed with AUGMENTIN on one side and 500/125 on the other. These physical characteristics help identify the specified branded presentation and distinguish it from the other conventional Augmentin tablet strengths.
The 500/125 marking reflects both active-component quantities. It should not be confused with an amoxicillin-only 500 mg tablet, which contains no clavulanate. The branded tablet description also differs from that of the conventional Augmentin 875/125 mg tablet, which is described as scored and capsule-shaped.
The FDA-described appearance is specific to the branded product. An independently approved generic 500/125 mg tablet may have a different imprint, shape, coating, color or inactive-ingredient composition. Such differences do not by themselves establish that the generic is incorrect or inferior. Product identity must be verified through approved labeling and the actual dispensing record.
The tablet itself is only one source of identification information. A pharmacy container label may provide the established or proprietary name, strength, directions, manufacturer or labeler and other details. An NDC can help identify the relevant packaged product, but it does not independently establish authenticity, FDA approval or current retail inventory.
Patients who receive a tablet with an unfamiliar appearance should ask the dispensing pharmacist to reconcile the product against the prescription and official labeling before using an uncertain medicine. For additional information about packaging and identifier checks, see the Augmentin product authenticity guide.
The 500/125 mg product identity extends beyond the tablet imprint. Official product labeling and package records can identify the specific drug name, strength, dosage form, labeler and National Drug Code. These details are useful when reconciling a pharmacy quotation with the product ultimately dispensed under an existing prescription.
A historical DailyMed label for branded Augmentin identifies 500 mg/125 mg tablet presentations in bottles of 20 and unit-dose packaging containing 100 tablets. Such records provide concrete examples of labeled package configurations, but their publication does not establish current brand distribution or local pharmacy inventory. The precise current product and package must be confirmed separately.
Different package identifiers can exist for the same nominal tablet strength because NDCs distinguish listed products and package configurations. Repackaged products may also display identifiers associated with a repackager rather than the original applicant. A labeler name therefore does not always identify the physical manufacturer or FDA application holder.
Generic products require additional care because an online catalog may group tablets from several companies under the same established drug name. The existence of a 500/125 mg generic entry is not evidence that a particular named manufacturer or package is presently available for dispensing. Marketing status, current pharmacy supply and FDA approval are distinct questions.
A useful verification sequence is to confirm the two active ingredients, complete strength pair, conventional tablet dosage form and actual dispensed package, then resolve any discrepancy with the pharmacist. No patient should be expected to establish medicine authenticity by interpreting an NDC alone.
| Identification record | What it can show | Important limitation |
|---|---|---|
| FDA prescribing information | 500 mg/125 mg active-component quantities and branded tablet appearance | Does not establish current local pharmacy stock. |
| Published branded package labeling | Historically labeled bottle and unit-dose package configurations | Historical packages may not represent current commercial supply. |
| Generic product label | Established drug name, strength, dosage form and labeler | The generic product may differ in appearance or packaging from the brand. |
| NDC | Drug-product or package-specific identification | Does not independently prove FDA approval, authenticity or availability. |
| Pharmacy dispensing record | Actual product and quantity supplied for an existing prescription | Must be reconciled with the prescription and any applicable substitution requirements. |
A frequent product-identification error is treating Augmentin 500/125 mg as though it were simply another brand name for amoxicillin 500 mg. The medicines are different. Plain amoxicillin contains amoxicillin as its sole antibacterial active ingredient, whereas Augmentin 500/125 mg contains amoxicillin together with clavulanate potassium.
The additional clavulanate component inhibits certain beta-lactamase enzymes and can affect activity against susceptible bacteria. This difference can be clinically relevant, but it does not make the combination universally stronger, safer or preferable. The appropriate antibiotic depends on the infection, bacterial susceptibility, patient history and applicable clinical guidance.
Plain amoxicillin 500 mg can also be supplied in dosage forms that differ from conventional Augmentin tablets. A pharmacy search result displaying amoxicillin 500 mg capsules or tablets is therefore not a match for a prescription explicitly identifying the 500/125 mg combination. A correct substitution cannot be inferred from the first number alone.
The distinction matters particularly when online product catalogs shorten medicine names, combine search results or display generic alternatives. Both the established drug name and the complete two-component strength must be checked before treating a listing as relevant to the existing prescription.
For a focused explanation of standalone amoxicillin products, see the amoxicillin 500 mg product guide. The separate Augmentin vs amoxicillin comparison explains the broader ingredient and prescribing differences without presenting either medicine as a universal replacement for the other.
The July 2026 FDA prescribing information specifically states that two conventional Augmentin 250 mg/125 mg tablets are not substitutable for one conventional Augmentin 500 mg/125 mg tablet. The restriction reflects the different total amount of clavulanic acid rather than a difference in the combined amount of amoxicillin.
Two 250/125 mg tablets provide 500 mg of amoxicillin and 250 mg of clavulanic acid in total. One 500/125 mg tablet provides the same 500 mg of amoxicillin but only 125 mg of clavulanic acid. Replacing the single 500/125 mg tablet with two lower-strength tablets would therefore double the clavulanate amount.
This example demonstrates why strength selection and formulation changes cannot be based solely on the amoxicillin quantity. Both active ingredients contribute to the product's identity, and different strength pairs cannot be assumed equivalent because their amoxicillin totals match.
The FDA also provides specific relationships for changing between certain conventional tablets and corresponding oral suspensions or chewable formulations. Those relationships are governed by Table 6 and applicable patient-population restrictions. They do not cancel the explicit prohibition on replacing one 500/125 mg tablet with two 250/125 mg conventional tablets.
Patients should not combine leftover tablets or alter a prescribed regimen to recreate a displayed strength. If a pharmacy cannot supply the originally prescribed presentation, an appropriate healthcare professional must determine whether another product or prescription adjustment is warranted.
The Augmentin 250/125 mg guide explains the lower-strength tablet and its 2:1 component ratio. The broader Augmentin tablets comparison places all three conventional tablet strengths in context.
| FDA-labeled tablet comparison | Amoxicillin total | Clavulanic acid total | Interpretation |
|---|---|---|---|
| One conventional 500/125 mg tablet | 500 mg | 125 mg | The prescribed product identity being compared. |
| Two conventional 250/125 mg tablets | 500 mg | 250 mg | Not substitutable for one 500/125 mg tablet under FDA labeling. |
| One conventional 250/125 mg tablet | 250 mg | 125 mg | A separate tablet strength with a different ingredient ratio. |
The relationship between a conventional 500/125 mg tablet and other Augmentin dosage forms is more specific than a general statement that tablets cannot be replaced with liquids. Section 2.8, Table 6 of the July 2026 FDA prescribing information identifies particular suspension and chewable strength families that can be considered when changing formulations under appropriate professional management.
For the conventional 500 mg/125 mg tablet, Table 6 lists 125 mg/31.25 mg and 250 mg/62.5 mg as corresponding oral suspension or chewable strengths. These presentations share a 4:1 amoxicillin-to-clavulanic-acid ratio. However, the amounts stated per chewable tablet or per 5 mL of suspension are not identical to the amounts in one 500/125 mg conventional tablet.
The FDA's table identifies strength-family relationships rather than instructing patients to exchange one unit for another. The relevant quantity, concentration and patient circumstances require professional assessment. In particular, the FDA restricts chewable tablets used as substitutes to pediatric patients weighing less than 40 kg, while conventional tablets have separate population requirements.
A 250/62.5 mg chewable tablet or 5 mL of the corresponding suspension contains 250 mg of amoxicillin and 62.5 mg of clavulanic acid. The conventional 500/125 mg tablet contains twice those component amounts. This relationship describes composition, not permission for a patient to calculate or change a prescribed dose independently.
The 125/31.25 mg suspension and chewable strength family also appears in the FDA table. As with the 250/62.5 mg family, the component ratio is relevant, but an appropriate formulation change must still account for the specific product, patient population and prescribing instructions.
The Augmentin oral suspension guide addresses concentration-based liquid labeling, while the Augmentin chewable tablets guide covers the separately labeled chewable products.
| FDA-labeled presentation | Amoxicillin | Clavulanic acid | Product relationship |
|---|---|---|---|
| 500/125 mg conventional tablet | 500 mg per tablet | 125 mg per tablet | The immediate-release tablet strength addressed by this page. |
| 250/62.5 mg chewable tablet | 250 mg per chewable tablet | 62.5 mg per chewable tablet | A 4:1 formulation family identified in FDA Table 6, subject to substitution restrictions. |
| 250/62.5 mg per 5 mL suspension | 250 mg per 5 mL | 62.5 mg per 5 mL | A 4:1 liquid concentration identified in FDA Table 6. |
| 125/31.25 mg chewable tablet | 125 mg per chewable tablet | 31.25 mg per chewable tablet | A 4:1 formulation family identified in FDA Table 6, subject to substitution restrictions. |
| 125/31.25 mg per 5 mL suspension | 125 mg per 5 mL | 31.25 mg per 5 mL | A 4:1 liquid concentration identified in FDA Table 6. |
An independently approved generic amoxicillin/clavulanate 500 mg/125 mg tablet is generally authorized through an Abbreviated New Drug Application, or ANDA. The FDA evaluates a generic against applicable requirements involving the reference product, pharmaceutical equivalence, bioequivalence, labeling and quality. The approval relationship is specific to the drug product rather than to the ingredient names alone.
The FDA Orange Book provides information about approved drug products and applicable therapeutic-equivalence evaluations. A generic tablet may be considered therapeutically equivalent to the appropriate reference product when the FDA assigns the relevant evaluation. However, this does not mean that products with different strengths, dosage forms or release characteristics are interchangeable.
The actual generic tablet may differ from the original branded presentation in imprint, appearance, inactive ingredients and packaging. These differences can be permitted under FDA requirements. A branded Augmentin tablet with the AUGMENTIN and 500/125 markings should therefore not be used as the universal physical-identification standard for every approved generic tablet.
The name appearing in a pharmacy database can identify an application holder, manufacturer, labeler, distributor or repackager. These roles should not be treated as identical. A current product inquiry may require comparing an FDA approval record with the published labeling and actual package supplied by the pharmacy.
Authorized generics represent another regulatory category. They are marketed without the original proprietary name under an approved brand NDA rather than necessarily having an independently approved ANDA. The phrase generic Augmentin does not by itself identify which approval pathway applies to a particular product.
Readers interested in official approval records can consult the FDA-approved Augmentin products guide. The generic amoxicillin/clavulanate manufacturers directory separately addresses applicant, manufacturer and labeler identities. This page remains focused on verifying the 500/125 mg tablet.
The conventional 500 mg/125 mg tablet occupies a defined position within the standard immediate-release tablet family. The conventional 250/125 mg and 875/125 mg tablets contain different quantities of amoxicillin while retaining 125 mg of clavulanic acid per tablet. Their component ratios and strength identities are therefore different.
The Augmentin 875/125 mg tablet guide covers the higher-amoxicillin conventional tablet presentation. Matching the clavulanate amount does not mean that the 500/125 mg and 875/125 mg tablets are freely substitutable. The prescribed strength must be verified independently.
Augmentin XR is a separate extended-release product containing 1,000 mg of amoxicillin and 62.5 mg of clavulanic acid per tablet. Its release characteristics and strength differ from those of conventional immediate-release tablets. The FDA explicitly states that two ordinary Augmentin 500 mg tablets are not equivalent to one Augmentin XR 1,000 mg tablet.
Augmentin ES-600 is a distinct oral suspension containing 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL after preparation. It has specific pediatric labeling and formulation characteristics. It is not a liquid version of the conventional 500/125 mg tablet.
The Augmentin XR product guide and Augmentin ES-600 guide describe those separately labeled formulations. Their existence reinforces why generic pharmacy searches must not group all amoxicillin/clavulanate products as interchangeable alternatives.
A U.S. pharmacy must process Augmentin 500/125 mg as a prescription-only medicine. A valid prescription and an appropriate dispensing review are required. The practical verification process begins by confirming that the prescribed product contains both amoxicillin and clavulanate potassium and that its intended strength is 500 mg/125 mg in the conventional immediate-release tablet form.
The distinction between branded and generic dispensing should be addressed before assuming a product match. If the prescription identifies Augmentin but a generic product is to be supplied, the pharmacist must consider the particular approved product, relevant therapeutic-equivalence information, prescription restrictions and applicable state requirements.
The pharmacy should be able to confirm the actual product name, dosage form, strength, manufacturer or labeler and relevant NDC where applicable. The NDC can help reconcile the dispensed package with published product information but does not independently establish FDA approval or guarantee that a pharmacy has a specific item in stock.
Pharmacy listings may display a brand name even when the supplied medicine is a generic. Conversely, an FDA approval record or historical package listing does not establish that the original branded package is currently in commercial distribution. Patients who require a specific product should request confirmation from the dispensing pharmacy.
If an expected brand or generic package cannot be supplied, any alternative must be assessed under the prescription and appropriate professional requirements. The existence of another strength pair or a corresponding liquid formulation should not be treated as permission for independent substitution.
For information about prescription-based pharmacy services, see the Augmentin online pharmacy guide. The Augmentin prescription evaluation guide separately explains clinical assessment and prescribing requirements. This page is limited to product identification for an existing prescription.
| Verification step | What to confirm | Reason |
|---|---|---|
| Prescription | Valid prescription identifying the intended medicine | Augmentin is not an over-the-counter drug. |
| Active ingredients | Amoxicillin and clavulanate potassium | Prevents confusion with plain amoxicillin 500 mg. |
| Strength | 500 mg amoxicillin and 125 mg clavulanic acid | Both quantities define the prescribed combination tablet. |
| Dosage form | Conventional immediate-release oral tablet | Distinguishes the product from XR, chewable and liquid forms. |
| Brand or generic | Actual product name and relevant FDA approval relationship | A brand-based search result does not establish the dispensed product. |
| Manufacturer or labeler | Company identified on the dispensed product | Supports reconciliation with the actual product label. |
| NDC and package | Product and package identifiers where available | Helps identify the supplied product without guaranteeing stock or approval. |
| Substitution rules | Applicable prescription restrictions and professional requirements | Prevents inappropriate changes between formulations or strengths. |
Augmentin 500/125 mg contains a penicillin-class antibacterial and is subject to the warnings and contraindications in the applicable FDA prescribing information. Serious hypersensitivity reactions to Augmentin or other beta-lactam antibacterial drugs are an important contraindication. Previous Augmentin-associated cholestatic jaundice or hepatic dysfunction is also identified in FDA labeling as a reason the medicine must not be used.
Common adverse reactions to amoxicillin/clavulanate can include diarrhea, nausea, vomiting and skin reactions. More serious events described in the labeling include anaphylaxis, severe skin reactions, liver injury and Clostridioides difficile-associated diarrhea. Sudden breathing difficulty, swelling of the face or throat or other signs of a severe allergic reaction require emergency medical attention.
The FDA also describes medication-interaction and patient-specific considerations. Drugs such as probenecid, oral anticoagulants and allopurinol may require attention during clinical review. Kidney function, allergy history and other medical factors can affect prescribing. The appropriate regimen cannot be determined from product strength information alone.
The 125 mg clavulanate component is relevant when comparing products, but patients should not use differences in clavulanate amounts to select or modify treatment independently. The explicit restriction against replacing one 500/125 mg tablet with two 250/125 mg tablets illustrates the importance of preserving the prescribed formulation.
Responsible antibacterial use requires an appropriate clinical indication and adherence to the instructions provided by the prescriber. Patients should not use leftover antibiotics, share medication or assume that a combination antibiotic is preferable for every infection. Augmentin does not treat viral illnesses such as influenza or the common cold.
For more information about beta-lactam hypersensitivity, see the penicillin allergy guide. This product page does not provide individualized allergy assessment or medical advice.
The FDA-approved identity of the 500 mg/125 mg tablet should be distinguished from current retail distribution. A branded product can have an established approval history and published labeling without being available from every pharmacy. Similarly, the existence of an approved generic does not guarantee that a specific manufacturer or package is currently stocked.
A pharmacy may provide information about available branded or generic 500/125 mg tablet products for an existing prescription. Any contemplated substitution must comply with the prescription, relevant approval and therapeutic-equivalence requirements and applicable pharmacy law. Patients should not select another tablet strength simply because the original package is unavailable.
Out-of-pocket costs can differ between branded and generic products and among pharmacies. Strength, quantity, manufacturer, insurance arrangements and applicable discounts may affect the actual transaction. A displayed price for plain amoxicillin 500 mg or another combination strength should not be treated as a quotation for Augmentin 500/125 mg.
For dedicated cost comparisons, see the Augmentin brand price guide and the generic amoxicillin/clavulanate price guide. The present page does not provide unverified price claims, insurance promises or assumptions about pharmacy stock.
The essential purchasing distinction is product accuracy: an existing prescription must be matched to an appropriate approved medicine, the complete 500/125 mg strength pair and the correct dosage form. Availability, cost and permitted substitution remain separate questions for the dispensing pharmacy.
Augmentin 500/125 mg is a prescription combination antibiotic tablet containing 500 mg of amoxicillin and 125 mg of clavulanic acid, supplied as clavulanate potassium. It belongs to the conventional immediate-release Augmentin tablet family.
The first number identifies 500 mg of amoxicillin, while the second identifies 125 mg of clavulanic acid. These are separate active-component quantities in one tablet, producing a 4:1 amoxicillin-to-clavulanic-acid ratio.
No. Plain amoxicillin 500 mg contains amoxicillin without clavulanate. Augmentin 500/125 mg contains both amoxicillin and clavulanate potassium. They are different medicines and should not be exchanged without professional assessment.
The July 2026 FDA prescribing information describes the branded tablet as white, oval and film-coated, debossed with AUGMENTIN on one side and 500/125 on the other. Generic versions may have different appearances and imprints.
Yes. The conventional 500/125 mg tablet is an immediate-release product. It is distinct from Augmentin XR, which is a separately labeled extended-release formulation with different release characteristics and component strengths.
The tablet contains 500 mg of amoxicillin and 125 mg of clavulanic acid, giving a 4:1 ratio. This ratio describes the product's composition and does not indicate comparative clinical superiority or provide dosing instructions.
No. Two 250/125 mg tablets provide 500 mg of amoxicillin but 250 mg of clavulanic acid. One 500/125 mg tablet contains 500 mg of amoxicillin and only 125 mg of clavulanic acid. The FDA explicitly states that these presentations are not substitutable.
The FDA identifies specific suspension strength families corresponding to the conventional 500/125 mg tablet, including 125/31.25 mg and 250/62.5 mg per 5 mL. These relationships are subject to the labeling and professional prescribing requirements. They are not permission for patients to independently calculate or change a prescribed dose.
No. One conventional 500/125 mg tablet contains twice the amount of each active component in one 250/62.5 mg chewable tablet. Although they share a 4:1 ingredient ratio, they are different dosage forms and strengths. Any formulation change requires professional assessment under the applicable labeling.
They are different conventional tablet strengths. Both contain 125 mg of clavulanic acid, but one contains 500 mg of amoxicillin and the other contains 875 mg. Patients should not change between them or adjust a prescribed regimen independently.
No. The FDA explicitly states that two conventional Augmentin 500 mg tablets are not equivalent to one Augmentin XR 1,000 mg tablet. XR has distinct release characteristics and a different clavulanate amount.
An appropriately FDA-approved generic may be therapeutically equivalent to the corresponding branded reference product when the applicable regulatory requirements are satisfied. The dosage form, complete strength pair, approval relationship and applicable substitution rules must be checked.
Yes. FDA-approved generic products may differ from the brand in appearance, imprint, inactive ingredients and packaging within applicable regulatory requirements. The actual tablet should be verified against its product label and pharmacy dispensing information.
A National Drug Code helps identify a drug product or package associated with a particular labeler. It can support product verification but does not independently establish FDA approval, medicine authenticity, clinical appropriateness or current pharmacy availability.
The branded Augmentin 500/125 mg tablet and corresponding FDA-approved generic products are identifiable through regulatory and product-label records. Their packaging and manufacturers may differ. Published product records do not guarantee that a particular brand or generic package is currently distributed or stocked.
No. Augmentin 500/125 mg is a prescription-only antibacterial medicine in the United States. Lawful dispensing requires a valid prescription and compliance with applicable pharmacy requirements. Online offers do not establish prescription-free access.
Confirm the prescribed and dispensed product names, both active ingredients, the full 500 mg/125 mg strength pair and the immediate-release tablet dosage form. Ask the pharmacist to verify the actual manufacturer or labeler, package and NDC where applicable.
No. Augmentin is used for specified infections caused by susceptible bacteria, but it is not universally appropriate or preferred. Clinical findings, bacterial susceptibility and patient-specific factors determine whether the medicine and prescribed regimen are suitable.
Augmentin contains amoxicillin, a penicillin-class antibacterial. Its FDA labeling contraindicates use in patients with a history of serious hypersensitivity reactions to Augmentin or other beta-lactam antibacterial drugs. A reported allergy requires professional evaluation before prescribing.
No. Leftover antibiotics should not be used for self-treatment. A new illness may have a different cause or may not require antibiotics. Unnecessary treatment can cause adverse effects and contribute to bacterial resistance.